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Abstract EBV-encoded small RNAs (EBERs) are non-poly-
adenylated and abundantly transcribed RNAs, whose functions
have not yet been fully elucidated. Here, we report that the EBV-
negative B lymphoma cell line, BJAB, was rendered more
malignant and resistant to apoptosis by EBERs. EBER-
transfected cells exhibited enhanced growth potential in SCID
mice as well as in soft agar, and showed resistance to apoptotic
stimuli in comparison with the vector control. EBERs inhibited
the activity of the double-stranded RNA-dependent protein
kinase, PKR, which is reputed to act as a tumor-suppressor.
These results suggest that EBERs play an important role in the
pathogenesis of EBV-associated malignancies through the
inhibition of PKR. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Epstein^Barr virus (EBV) is a ubiquitous human Q herpes
virus that establishes a life-long latent infection in its host.
EBV is associated with malignant diseases, including Burkitt’s
lymphoma (BL) [1,2], nasopharyngeal carcinoma [3,4], and
immunoblastic B cell lymphoma of immunosuppressed indi-
viduals. In these diseases, the di¡erent patterns of viral gene
expression are classi¢ed as type 1 latency for BL, type 2 la-
tency for nasopharyngeal carcinoma and type 3 latency for
immunoblastic B cell lymphoma of immunosuppressed indi-
viduals.
In type 1 latency, viral gene expression is restricted to two
proteins and two non-coding RNAs. The proteins are EBV-
associated nuclear antigen 1(EBNA-1) and RK-BARF0, and
the RNAs are EBV-encoded small RNA-1 and 2 (EBER-1
and EBER-2). In type 2 latency, integral membrane proteins
(LMPs) are present in addition to all the genes expressed in
type 1 latency. In type 3 latency, all the following viral latent
genes are expressed: six EBNAs, three LMPs, RK-BARF0
and EBERs.
It has been reported that the type 1 latency program of
EBV is closely related to the malignant phenotype of the
BL cell line [5,6]. Moreover, infection of epithelial cells with
EBV was shown to induce type 1 latency and result in malig-
nant phenotypes [7]. These results suggest that type 1 latency
genes of EBV may play important roles in the establishment
of malignant phenotypes.
Of all genes expressed in type 1 latency, we focused on
EBERs as the genes responsible for malignant phenotypes
because they have been reported to inhibit double-stranded
RNA-dependent protein kinase, PKR, which is described as
an anti-oncogene product [8,9].
PKR was identi¢ed initially as an interferon-inducible en-
zyme that became activated during virus infection [10^12]. It
is constitutively expressed in mammalian cells and is assumed
to function in the control of cell proliferation. Upon activa-
tion, PKR exhibits two kinase reactions: autophosphorylation
and phosphorylation of substrates such as eukaryotic initia-
tion factor (eIF) 2K. Phosphorylation of eIF2K results in a
decreased proliferation rate by inhibiting protein synthesis at
the translational initiation step [13,14]. Over-expression of
wild-type PKR inhibits the growth of yeast cells [15] and in-
duces apoptosis of HeLa cells [16,17], while dominant nega-
tive mutants of PKR confer malignant phenotypes onto
NIH3T3 cells [18^20]. Furthermore, recent studies have
shown that PKR may be involved in stress-induced apoptosis
[21^23], signal transduction and transcriptional control [24].
These results suggest that PKR may have a tumor-suppressor
function.
In this report we demonstrate that an EBV-negative B lym-
phoma cell line, BJAB, was rendered more malignant and
resistant to apoptosis by EBERs, which have an inhibitory
e¡ect on the tumor-suppressor activity of PKR.
2. Materials and methods
2.1. Cell culture
BJAB is an EBV-negative B lymphoma cell line. Cell lines were
maintained in RPMI 1640 medium supplemented with 10% fetal bo-
vine serum and 2 mM L-glutamine at 37‡C in 5% CO2 humidi¢ed
atmosphere.
2.2. Plasmids and transfection
EBERs and their promoters on the EcoRI J fragment of EBV were
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ampli¢ed by the polymerase chain reaction (PCR) with primers 5P-
CTCGGAGCTCCTAGGTCAGAC-3P (5Psequence) and 5P-GCATA-
TACAGTCAGCATATG-3P (3Psequence). The ampli¢ed fragment
was cloned into the pGEM-T vector (Promega). Both pcDNA3 vector
(Invitrogen) and pGEM-T/EBERs were digested by AatII and NotI,
and the fragment of EBERs was ligated into the pcDNA3 vector.
Vector plasmids with or without EBERs were introduced into BJAB
cells by electroporation as follows: 5U106 cells were washed twice
with serum-free RPMI 1640 and resuspended in 200 Wl of ice-cold
K-PBS containing 20 Wg of linearized plasmid DNA. Electroporation
was performed in the 4-mm gap cuvette with the Gene Pulser at 250 V
and 975 WF. To generate clonal transfectants, the cells were trans-
ferred to 96-well tissue culture plates (5U103 cells/ml) at 48 h post-
transfection, and cultured in 200 Wl of medium containing 800 Wg/ml
of G418. Half of the medium was changed every 6 days until colonies
emerged.
2.3. Northern blot analysis
Total RNA was extracted from BJAB cells with Isogen (Nippon
Gene) according to the manufacturer’s instructions. 10 Wg of total
RNA was loaded in each lane and separated on a 1.5% agarose gel
containing 0.66 M formaldehyde. Total RNA was transferred to Hy-
bond N+ nylon membranes (Amersham) and ¢xed with a UV cross
linker (Spectronics Corporation). Ribosomal RNA 18S and 28S
stained with ethidium bromide were visualized using the FLA 2000
system (Fuji Photo Film Co., Tokyo, Japan). Probes were ampli¢ed
by PCR with primers 5P-AGGACCTACGCTGCCCTAGA-3P and
5P-AAAACATGCGGACCACCAG-3P for EBER 1, and 5P-AGG-
ACAGCCGTTGCCCTA-3P and 5P-AAAAATAGCGGACAAGCC-
GA-3P for EBER 2. These probes were radiolabeled with a DNA
labeling kit (Nippon Gene). Membranes were prehybridized and hy-
bridized with labeled probes in the bu¡er (40% deionized formamide,
4USSC, 10% dextran sulfate, 1UDenhardt’s solution, 40 Wg/ml soni-
cated and denatured salmon sperm DNA, 0.1% SDS, 20 mM Tris (pH
7.5)) at 42‡C for 16 h. The membranes were washed twice for 15 min
at room temperature, and once for 30 min at 56‡C with 2USSC
containing 0.1% SDS, and exposed using a Fuji Imaging Plate. Radio-
activity was detected with the BAS system (Fuji Photo Film Co.,
Tokyo, Japan).
2.4. Colony formation assays
For the colony formation assays, 103 cells were suspended in 4 ml
of standard growth medium containing 0.5% soft agarose (SeaPlaque;
FMC). The suspension was embedded into a base layer made of 3 ml
of the same medium containing 0.6% soft agarose in 6-cm-diameter
tissue culture dish. The number of colonies larger than 0.5 mm was
counted after 3 weeks of incubation.
2.5. Tumorigenicity assays
Tumorigenicity of EBER-transfected and vector-transfected BJAB
cells was assessed by the ability to induce tumors in SCID mice.
Female SCID mice (C.B-17/lcr-scid Jcl ;CLEA) were injected subcuta-
neously in each hind £ank with 1U107 cells suspended in 200 Wl of
serum-free RPMI1640 medium. Each mouse received an injection of
EBER-transfected BJAB cells in the right £ank and vector-transfected
BJAB cells in the left £ank. SCID mice were monitored for 6 weeks to
measure the tumors that developed.
2.6. Induction and detection of apoptosis
For the induction of apoptosis, cells were exposed to anti Fas
monoclonal antibody (250 ng/ml) or mitomycin C (10 Wg/ml). The
cells were incubated for 16 h after stimulation, washed twice with
phosphate-bu¡ered saline (PBS), and suspended in 100 Wl of binding
bu¡er containing £uorescein-conjugated annexin V and propidium
iodide (Trevigen). After 30 min of incubation at 20^25‡C in the
dark, the cells were diluted with 400 Wl of binding bu¡er, and ana-
lyzed with FACScalibur for the detection of apoptosis.
2.7. Immunoprecipitation
For immunoprecipitation, 1U106 of EBER-transfected and vector-
transfected BJAB cells were washed by PBS and lysed in 100 Wl of
Bu¡er 1 (20 mM Tris^HCl pH 7.6, 50 mM KCl, 400 mM NaCl, 1 mM
EDTA, 5 mM 2-mercaptoethanol, 1% Triton X-100, 0.2 mM PMSF,
100 U/ml aprotinin, 20% glycerol, 100 WM Na3VO4, 20 mM L-glyc-
erophosphate). Cell lysates were incubated on ice for 10 min and
centrifuged at 15 000 rpm for 10 min at 4‡C. 0.3 Wl of anti-PKR
monoclonal antibody was added to supernatants and lysates were
incubated on ice for 20 min. After addition of 20 Wl of protein G
Sepharose suspension, cell lysates were gently agitated at 4‡C for 1 h,
washed four times with Bu¡er 1, and washed once with Bu¡er 3 (20
mM Tris^HCl pH 7.6, 80 mM KCl, 5 mM 2-mercaptoethanol, 2 mM
MgCl2, 2 mM MnCl2, 20% glycerol, 100 WM Na3VO4, 20 mM
L-glycerophosphate).
2.8. Kinase assay
Immunoprecipitated PKR was incubated with [Q-32P]ATP (3000 Ci/
mmol, NEN Life Science Products, Inc.), in the presence or absence of
poly(I)poly(C) at a concentration of 0.2 Wg/ml at 30‡C for 15 min, and
then with 3 Wg of histone H2A (Boehringer Mannheim, Germany),
which is an e¡ective substrate of PKR, at 30‡C for 15 min. The
phosphorylation reaction was stopped by adding 2Usample bu¡er
(60 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100 mM DTT, 0.1%
BPB). SDS^PAGE was then performed and phosphorylated H2A
proteins were visualized by the BAS system (Fuji Photo Film Co.,
Tokyo, Japan).
2.9. Western blot analysis
After the immunoprecipitation of PKR, protein G Sepharose beads
bound to PKR via antibody were suspended in 20 Wl of sample bu¡er
(250 mM Tris pH 6.8, 4% SDS, 20% glycerol, 0.2% BPB), and sam-
ples were boiled with 2-mercaptoethanol at 100‡C for 3 min. PKR
and the other precipitated molecules detached from protein G Sephar-
ose were separated in 10% polyacrylamide gel and transferred to a
PVDF membrane (Atto, Tokyo, Japan). The membrane was blocked
in PBS containing 3% milk and 0.1% Tween 20. For immunostaining,
the membrane was incubated with rabbit anti-PKR polyclonal anti-
body (Santacruz). PKR protein was detected with the FLA 2000
system (Fuji Photo Film Co., Tokyo, Japan).
3. Results
3.1. Vector- and EBER-transfected BJAB cell clones were
successfully established
To investigate the function of EBERs, we introduced an
EBER-cloned vector or control vector into BJAB cells and
established several clones of both transfectants (Fig. 1). The
expression levels of EBERs in EBER-transfected cells were
approximately 40^60% of those in Raji cells, which constitute
an EBV-positive Burkitt’s lymphoma cell line. Northern blot
analysis revealed a higher level of EBER-1 transcript expres-
sion than EBER-2 transcript expression in both Raji cells and
EBER-transfected cell clones.
3.2. EBERs enhanced the growth potential of the B lymphoma
cell line, BJAB
To evaluate the e¡ects of EBERs, we ¢rst compared the
Fig. 1. Northern blot analysis of EBER-1 and EBER-2 expression
in Raji and established transfectants. 10 Wg of total RNA was
loaded in each lane.
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growth kinetics of EBER-transfected BJAB cells with those of
vector controls at the serum concentration of 10% (Fig. 2A).
In the logarithmic phase (day 1^3), EBER-transfected BJAB
cells exhibited higher growth rates than the vector control in
the presence of 10% serum. In the stationary phase (day 4^5),
EBER-positive cells reached higher saturation densities than
vector-transfected BJAB cells at the serum concentration of
10%.
We also investigated the growth kinetics of EBER- and
vector-transfected BJAB cells under limited serum concentra-
tions (Fig. 2B). EBER-transfected BJAB cells survived at low
serum concentrations in comparison with vector-transfected
BJAB cells, which suggests that EBERs inhibited apoptosis
induced by serum deprivation.
To determine whether or not EBERs confer enhanced
growth potential and tumorigenicity, we examined EBER-
and vector-transfected BJAB cells for their ability to form
colonies in soft agar (Fig. 3) and tumor generation in SCID
mice (Table 1). Although vector-transfected BJAB cells exhib-
ited limited ability to produce colonies in soft agar, EBER-
transfected BJAB cells formed many larger colonies. In terms
of tumorigenicity in SCID mice, EBER-transfected BJAB cells
produced tumors at the sites of inoculation in 10 of 10 SCID
mice, while vector-transfected BJAB cells did so in only 1 of
10 SCID mice (Table 1). Even in the mouse in which EBER-
and vector-transfected cells formed a tumor, the size of the
tumor from vector-transfected cells was much smaller than
that from EBER-transfected cells.
3.3. EBERs conferred resistance to apoptosis induced by
several stimuli
From the results indicating that EBERs contribute to sur-
vival of BJAB cells under growth-limiting conditions, we pre-
dicted that EBERs might inhibit stress-induced apoptosis. To
determine whether EBERs endow resistance to apoptosis, cells
were exposed to several apoptotic stimuli (anti-Fas monoclo-
nal antibody and mitomycin C). Next, cells were subjected to
staining with annexin V, which is a marker for early stage
apoptosis and PI, which is a marker for late stage apoptosis
(Fig. 4). Viable cells were those that were not stained by either
annexin V or PI. The proportions of viable cells exposed to
various apoptotic stimuli were signi¢cantly higher in EBER-
transfected BJAB cells than in vector-transfected BJAB cells.
These results suggest that EBERs may act as inhibitors of
apoptosis induced by di¡erent stimuli.
Fig. 2. Growth characteristics of EBER-transfected and vector-transfected BJAB cells. A: Growth curves of BJAB cells at a 10% serum concen-
tration. EBER-transfected (shaded symbols) and vector-transfected (open symbols) BJAB cells were seeded at 1U105 cells/ml in growth medium
containing 10% FCS, and cell density was monitored daily for 5 days to assess growth rate. B: Growth curves of BJAB cells at a low serum
concentration. Cells were washed and seeded at 4U105 cells/ml in growth medium containing 0.1% FCS. Cell density was monitored daily for
5 days.
Table 1
Tumorigenicity of BJAB cells in SCID mice
Cell line Number of mice tumor(+)/total Length/width/height of developed tumor (mm)
EBER-transfected BJAB 10/10 23.8/15.8/7.6a
Vector-transfected BJAB 1/10 10/9/3
Tumorigenicity of EBER-transfected and vector-transfected BJAB cells in SCID mice. Each mouse received an injection of vector-transfected
BJAB cells (clone #1) in the left £ank and EBER-transfected BJAB cells (clone #1) in the right £ank. The size of formed tumors was measured
6 weeks after inoculation.
aMean value.
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3.4. EBERs inhibit activation of PKR, a mediator of various
apoptotic signals
We carried out an in vitro kinase assay to investigate
whether in BJAB cells, the stem^loop structure of EBERs
can activate or inhibit the kinase activity of PKR. The results
of the kinase assay are shown in Fig. 5. PKR immunopre-
cipitated from EBER-transfected cells exhibited lower kinase
activity than that from the vector control, although the
amounts of PKR protein were almost the same in both types
of cells. PKR phosphorylated itself and its substrate, H2A,
e⁄ciently when incubated with polyIC. Even in the absence of
polyIC, we detected autophosphorylation of PKR and phos-
phorylation of H2A. These results suggested that EBERs were
able to inhibit the kinase activity of PKR by binding to this
kinase.
4. Discussion
We have demonstrated that EBERs bestow enhanced
growth potential and apoptosis resistance on BJAB cells. In
the analysis of growth potential, it seemed that di¡erent
growth properties were manifest under growth-limiting con-
ditions such as con£uent cultures, low-serum-concentrations
and in vivo growth in SCID mice. Since EBERs comprise only
non-polyadenylated small RNAs, it is interesting that EBERs
can exert the malignant transformation activity that we have
described.
According to a previous report, EBER-negative recombi-
nant forms of EBV could still immortalize B lymphocytes in
culture [25]. However, this immortalization of B lymphocytes
was in the context of type 3 latency, which is di¡erent from
the type 1 latency seen in Burkitt’s lymphoma. It is probable
Fig. 3. Colony formation of EBER- and vector-transfected BJAB
cells in soft agar. BJAB cells were plated in 0.5% soft agarose at a
density of 103 cells/6-cm-diameter dish. The number of colonies was
counted 3 weeks after plating. These results were the average of
three independent experiments. The vertical bars represent standard
errors of the mean.
Fig. 4. Resistance to apoptosis induced by several stimuli. EBER-transfected and vector-transfected BJAB cells were exposed for 16 h to vari-
ous inducers of apoptosis. They were then incubated with £uorescein isothiocyanate-conjugated annexin V and propidium iodide. Stained cells
were measured with FACScalibur. Each number represents the percentage of viable cells (lower left), early apoptotic cells (lower right) and late
apoptotic cells (upper right). The ¢gures are the representative results obtained from three independent experiments with vector-transfected
BJAB clone #1 and EBER-transfected BJAB clone #1. We observed essentially the same results in all the other clones.
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that EBERs play an important role in malignant transforma-
tion in the context of type 1 latency, but not in immortal-
ization in the context of type 3 latency.
The proliferation rate of EBER-transfected BJAB cells in
the medium containing 10% FCS was higher than that of
vector-transfected cells at the logarithmic phase, and the sat-
uration density was higher than that of vector controls at the
stationary phase. Furthermore, EBER-transfected BJAB cells
survived at a lower serum concentration in comparison with
vector-transfected BJAB cells. These results strongly suggested
that EBERs possess the ability to inhibit apoptosis induced by
saturation and serum deprivation. EBERs may act as genes
inhibiting apoptosis, whose expression is required for trans-
formation.
In addition to saturation and serum deprivation, EBERs
exhibited resistance to apoptosis induced by stress such as
Fas and mitomycin C. These ¢ndings indicate that EBERs
can inhibit a variety of apoptotic signals and that EBERs
may target the common pathway associated with various
types of apoptosis.
In general, it has been said that the transformation of cells
requires expression of at least two kinds of genes: genes like c-
myc promoting cell growth, and genes like bcl-2 inhibiting
apoptosis. EBER-transfected BJAB cells proliferated faster
than vector-transfected BJAB cells at a serum concentration
of 10%, and EBER-positive cells were able to grow in soft
agar and in SCID mice more e⁄ciently than the vector con-
trols. These data show that EBERs have not only anti-apo-
ptotic e¡ects, but also growth-promoting e¡ects. According to
previous reports, EBV-converted BJAB cells were able to
grow in soft agar and these convertants exhibited an increased
expression of c-myc [26,27]. Another report suggested that
EBV enhances tumorigenicity and resistance to apoptosis
through the regulation of c-myc and bcl-2 in the context of
the type 1 latency program [6]. The c-myc oncogene has been
shown to contribute to tumorigenesis and induction of apo-
ptosis [28^30]. Therefore, it is possible that the anti-apoptotic
activity of EBERs may play a role in protecting cells from c-
myc-induced apoptosis, thereby allowing c-myc to exert its
oncogenic activity.
EBERs are highly expressed transcripts, which have a stem-
loop structure that is a kind of double-stranded RNA struc-
ture. So far, at least three functions have been ascribed to
EBERs as follows. Firstly, EBERs bind to the PKR and in-
terfere with its kinase activity [8,9] ; Secondly, EBERs bind to
the lupus antigen La protein [31]; Thirdly, EBERs bind to the
ribosomal protein L22 and sequester L22 in the nucleus
[32,33].
PKR has been extensively investigated as a regulator of
translation, signal transduction, cell cycle and apoptosis
[13,24,34]. Activation of PKR results in the phosphorylation
of eIF-2K and the inhibition of protein synthesis. PKR can
phosphorylate IUBK and induce the activation of nuclear fac-
tor-UB (NF-UB) [24,35,36], which leads to the expression of
Fas [37,38]. PKR may cause apoptotic cell death through up-
regulation of Fas [39]. In addition, a connection between PKR
and p53 has been reported [40^42]. The ectopic expression of
catalytically inactive mutants of PKR in NIH3T3 cells led to
the formation of tumors in nude mice [18] and the resistance
to apoptosis induced by various stresses such as serum-depri-
vation, TNF-K and Fas-induced signals [22,43]. PKR was
shown to be a mediator of stress-induced apoptosis by in vitro
studies using PKR knockout mouse embryo ¢broblasts as well
[21,23]. Moreover, the ectopic expression of two cellular in-
hibitors of PKR, p58 and HIV-1 TAR RNA binding protein
TRBP, also resulted in the malignant transformation of cells
[44,45]. Considering the important roles of PKR in cell
growth and apoptosis, EBERs may induce malignant trans-
formation of BJAB cells through the inhibition of PKR func-
tion. Our observation that the phosphorylation level of H2A
by PKR is lower in EBER-transfectants as compared to vec-
tor control supports this notion.
It has been reported that in the case of murine NIH 3T3
cell lines, the stable expression of EBER-1 results in a mor-
phologically transformed phenotype and confers the ability to
form colonies in soft agar [46]. Very recently, Komano et al.
reported that EBV-negative clones of the Akata cell line
(which was derived from a patient with EBV-positive Japa-
nese Burkitt’s lymphoma) displayed a more malignant nature
when transfected with EBERs relative to the vector control
[47]. The authors suggested that EBERs may exhibit oncogen-
ic e¡ects through the up-regulation of bcl-2.
We have shown that EBERs have oncogenic potential and
an inhibitory e¡ect on PKR, and attempts are underway to
determine the nature of these RNAs and to clarify the mech-
anism of EBER-induced transformation.
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